Evie Carchman, MD, FACS
Associate Professor
- Division of Colorectal Surgery
carchman@surgery.wisc.edu
(608) 262-0422
- Administrative Assistant: (608) 263-2521
Clinical Science Center
600 Highland Avenue
Madison, WI 53792-7375
Education
- MD, Medical College of Virginia at Virginia Commonwealth University, Richmond, VA
- General Surgery Residency, University of Pittsburgh Medical Center, Pittsburgh, PA
- Colon and Rectal Surgery Fellowship, Cleveland Clinic, Cleveland, OH
Clinical Specialties
Dr. Evie Carchman is a fellowship-trained colon and rectal surgeon. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.
Dr. Carchman provides a wide range of services including Abdominoperineal Resection, Abscess Drainage, Endorectal Advancement Flap, Fistulotomy, Flap Repair, Hemorrhoid Banding, Hemorrhoidectomy, Ileocolic Resection, Laparoscopic and Open Partial Colectomy, Laparoscopic and Open Rectopexy, Laparoscopic and Open Sigmoid Resection, Laparoscopic and Open Total Colectomy, Lateral Internal Sphincterotomy, Lower Anterior Resection (LAR), Pilonidal Cyst Excision, Sphincter Repair (overlapping sphincteroplasty), Total Proctocolectomy, Transanal Proctosigmoidectomy.
Research Interests
Dr. Carchman’s Research Lab >>
Dr. Carchman’s research interests focus on the pathogenesis and treatment of anal cancer. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.
Recent Publications
Carboplatin and Paclitaxel Chemoradiation for Localized Anal Cancer in Patients Not Eligible for Mitomycin and 5-Fluorouracil.
DeZeeuw AK, Bassetti MF, Carchman EH, Heise CP, Hayden D, Lawson EH, Sanger CB, King R, LoConte NK, Lubner SJ, Kratz JD, Deming DA
Cancers (Basel) 2024 Sep 03; 16(17)
[PubMed ID: 39272920]A phase I study of intra-anal artesunate (suppositories) to treat anal high-grade squamous intraepithelial lesions.
Fang SH, Plesa M, Carchman EH, Cowell NA, Staudt E, Twaroski KA, Buchwald UK, Trimble CL
PLoS One 2023; 18(12): e0295647
[PubMed ID: 38100463]Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert PF, Harari PM, Rimm DL, Burtness B, Grasic Kuhar C, Carchman EH
Viruses 2023 Nov 25; 15(12)
[PubMed ID: 38140561]Preclinical Models of Anal Cancer Combined-Modality Therapy.
Johnson HR, Gunder LC, Gillette A, Sleiman H, Rademacher BL, Meske LM, Culberson WS, Micka JA, Favreau P, Yao E, Matkowskyj KA, Skala MC, Carchman EH
J Surg Res 2024 Feb; 294: 82-92
[PubMed ID: 37864962]Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.
Gunder LC, Johnson HR, Yao E, Moyer TH, Green HA, Sherer N, Zhang W, Carchman EH
Viruses 2023 Apr 20; 15(4)
[PubMed ID: 37112993]